Allucent has received a $25.5m Biomedical Advanced Research and Development Authority (BARDA)-funded grant to support a Covid-19 vaccine decentralised clinical trial.
The award granted through the Rapid Response Partnership Vehicle (RRPV) Consortium is part of Project NextGen.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The trial will focus on establishing correlates of protection (CoPs) in a geographically diverse population to understand the range of immunologic responses to Covid-19 and its vaccines.
By leveraging its expertise in DCTs, Allucent aims to facilitate broader participation and reduce the burdens typically associated with clinical trial involvement.
The company will initiate a 4,000-participant decentralised Phase IV observational study using the project award.
The study will evaluate CoPs following vaccination with a US Food and Drug Administration (FDA)-approved or authorised vaccine.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAllucent’s customised DCT model will be used in the trial to enhance the participant experience.
The trial will explore the feasibility of remote, self-collected specimens for CoP analysis and will incorporate wearable devices to potentially predict Covid-19 infections.
The insights gained from the data collected will contribute to the ongoing efforts to combat the Covid-19 pandemic.
Allucent chairman and CEO Mark Goldberg said: “We are proud to apply our decentralised trial expertise as a partner to BARDA on this initiative.
“The continuing emergence of new variants and subvariants underscores the need for ongoing optimisation of Covid-19 vaccines to ensure their effectiveness in combating the virus. This study is a step forward in addressing the evolving challenges posed by Covid-19 and mitigating their impact on public health.”
Decentralised Clinical Trial coverage in Clinical Trials Arena is supported by Huma.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
